Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California and currently employs 14 full-time employees. The company went IPO on 2021-11-26. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

Industry: Pharmaceutical Preparations Peers: Oruka Therapeutics Inc Tectonic Therapeutic Inc Orgenesis Inc. Soleno Therapeutics Inc Eledon Pharmaceuticals Inc Vistagen Therapeutics Inc Maia Biotechnology Inc Shuttle Pharmaceuticals Holdings Inc Tonix Pharmaceuticals Holding Corp